| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
In the preceding three months, 13 analysts have released ratings for Vertex Pharmaceuticals (NASDAQ:VRTX), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 4 | 4 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 2 | 1 | 1 | 0 | 0 |
| 2M Ago | 0 | 1 | 1 | 0 | 0 |
| 3M Ago | 3 | 2 | 1 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $477.54, a high estimate of $555.00, and a low estimate of $421.00. This current average has increased by 4.91% from the previous average price target of $455.18.
The standing of Vertex Pharmaceuticals among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Matthew Harrison | Morgan Stanley | Raises | Equal-Weight | $455.00 | $402.00 |
| Steve Chesney | Redburn Atlantic | Announces | Buy | $545.00 | - |
| Mohit Bansal | Wells Fargo | Raises | Overweight | $555.00 | $540.00 |
| Jasper Hellweg | Argus Research | Raises | Buy | $550.00 | $465.00 |
| Brian Abrahams | RBC Capital | Lowers | Sector Perform | $421.00 | $424.00 |
| Brian Abrahams | RBC Capital | Maintains | Sector Perform | $424.00 | $424.00 |
| Evan Seigerman | BMO Capital | Raises | Outperform | $500.00 | $480.00 |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $462.00 | $462.00 |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $424.00 | $417.00 |
| Christopher Raymond | Piper Sandler | Raises | Overweight | $456.00 | $450.00 |
| Debjit Chattopadhyay | Guggenheim | Raises | Buy | $450.00 | $445.00 |
| Colin Bristow | UBS | Lowers | Buy | $466.00 | $498.00 |
| Hartaj Singh | Oppenheimer | Maintains | Outperform | $500.00 | - |
For valuable insights into Vertex Pharmaceuticals's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Vertex Pharmaceuticals analyst ratings.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Positive Revenue Trend: Examining Vertex Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 13.3% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Vertex Pharmaceuticals's net margin excels beyond industry benchmarks, reaching 40.87%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Vertex Pharmaceuticals's ROE excels beyond industry benchmarks, reaching 6.09%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Vertex Pharmaceuticals's ROA stands out, surpassing industry averages. With an impressive ROA of 4.71%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Vertex Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 0.04, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: VRTX
